MX2023002695A - Virus adeno-asociado para la administración de kh902 (conbercept) y usos del mismo. - Google Patents
Virus adeno-asociado para la administración de kh902 (conbercept) y usos del mismo.Info
- Publication number
- MX2023002695A MX2023002695A MX2023002695A MX2023002695A MX2023002695A MX 2023002695 A MX2023002695 A MX 2023002695A MX 2023002695 A MX2023002695 A MX 2023002695A MX 2023002695 A MX2023002695 A MX 2023002695A MX 2023002695 A MX2023002695 A MX 2023002695A
- Authority
- MX
- Mexico
- Prior art keywords
- variants
- vegf
- aav2
- conbercept
- adeno
- Prior art date
Links
- 241000702421 Dependoparvovirus Species 0.000 title 1
- 108700036276 KH902 fusion Proteins 0.000 title 1
- 229950005748 conbercept Drugs 0.000 title 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 abstract 1
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 abstract 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 abstract 1
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000002137 anti-vascular effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063074361P | 2020-09-03 | 2020-09-03 | |
| US202163179700P | 2021-04-26 | 2021-04-26 | |
| PCT/US2021/048917 WO2022051537A1 (en) | 2020-09-03 | 2021-09-02 | Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002695A true MX2023002695A (es) | 2023-05-19 |
Family
ID=80491540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002695A MX2023002695A (es) | 2020-09-03 | 2021-09-02 | Virus adeno-asociado para la administración de kh902 (conbercept) y usos del mismo. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230340529A1 (https=) |
| EP (1) | EP4208478A4 (https=) |
| JP (1) | JP2023540094A (https=) |
| KR (1) | KR20230061441A (https=) |
| AU (1) | AU2021336425A1 (https=) |
| BR (1) | BR112023003548A2 (https=) |
| CA (1) | CA3192736A1 (https=) |
| IL (1) | IL300864A (https=) |
| MX (1) | MX2023002695A (https=) |
| WO (1) | WO2022051537A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020006435A (es) | 2017-12-19 | 2021-02-09 | Akouos Inc | Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno. |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| AU2024247959A1 (en) * | 2023-03-28 | 2025-10-09 | General Medicines Llc | Nucleic acid off-switches and methods and uses thereof |
| WO2024220389A2 (en) * | 2023-04-17 | 2024-10-24 | University Of Massachusetts | Aav2 variants and uses thereof |
| CN119656336A (zh) * | 2023-09-21 | 2025-03-21 | 成都弘基生物科技有限公司 | 一种重组腺相关病毒在制备治疗与血管新生相关眼病的药物中的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100897379B1 (ko) * | 2004-06-08 | 2009-05-14 | 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 | 혈관신생-저해 키메릭 단백질 및 그 사용 |
| AU2014286996A1 (en) * | 2013-07-12 | 2016-01-07 | Iveric Bio, Inc. | Methods for treating or preventing ophthalmological conditions |
| EP3134522B1 (en) * | 2014-04-25 | 2021-10-06 | University of Massachusetts | Recombinant aav vectors useful for reducing immunity against transgene products |
| US11046955B2 (en) * | 2015-04-24 | 2021-06-29 | University Of Massachusetts | Modified AAV constructs and uses thereof |
| DK3471780T3 (da) * | 2016-06-16 | 2020-11-23 | Adverum Biotechnologies Inc | Behandling af amd med aav2-variant med aflibercept |
| AU2018227483A1 (en) * | 2017-02-28 | 2019-09-12 | Adverum Biotechnologies, Inc. | Modified AAV capsids and uses thereof |
| AU2018350990A1 (en) * | 2017-10-18 | 2020-05-21 | Regenxbio Inc. | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap |
| KR102205830B1 (ko) * | 2017-10-26 | 2021-01-21 | 주식회사 큐로진생명과학 | 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물 |
| US11103552B2 (en) * | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
-
2021
- 2021-09-02 BR BR112023003548A patent/BR112023003548A2/pt unknown
- 2021-09-02 MX MX2023002695A patent/MX2023002695A/es unknown
- 2021-09-02 CA CA3192736A patent/CA3192736A1/en active Pending
- 2021-09-02 WO PCT/US2021/048917 patent/WO2022051537A1/en not_active Ceased
- 2021-09-02 JP JP2023514415A patent/JP2023540094A/ja active Pending
- 2021-09-02 KR KR1020237010791A patent/KR20230061441A/ko active Pending
- 2021-09-02 AU AU2021336425A patent/AU2021336425A1/en active Pending
- 2021-09-02 EP EP21865133.9A patent/EP4208478A4/en active Pending
- 2021-09-02 IL IL300864A patent/IL300864A/en unknown
- 2021-09-02 US US18/024,359 patent/US20230340529A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022051537A1 (en) | 2022-03-10 |
| EP4208478A4 (en) | 2025-04-02 |
| CA3192736A1 (en) | 2022-03-10 |
| EP4208478A1 (en) | 2023-07-12 |
| IL300864A (en) | 2023-04-01 |
| JP2023540094A (ja) | 2023-09-21 |
| US20230340529A1 (en) | 2023-10-26 |
| BR112023003548A2 (pt) | 2023-04-04 |
| AU2021336425A1 (en) | 2023-03-16 |
| KR20230061441A (ko) | 2023-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002695A (es) | Virus adeno-asociado para la administración de kh902 (conbercept) y usos del mismo. | |
| US11491242B2 (en) | AAV vectors targeted to the central nervous system | |
| MX2020005451A (es) | Capsides variantes de virus adenoasociados y uso para inhibir la angiogenesis. | |
| KR101835490B1 (ko) | 신경변성 질환에 대한 유전자 요법 | |
| KR102554850B1 (ko) | 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도 | |
| ES2911714T3 (es) | Proteína M013 expresada por AAV como un terapéutico antiinflamatorio para su uso en un método de tratamiento de enfermedad ocular inflamatoria | |
| MX2023009627A (es) | Capsides variantes de virus adenoasociados y metodos de uso de las mismas. | |
| MX2020003176A (es) | Variantes de capsides de virus adenoasociados y metodos de uso de estas. | |
| ES2871527T3 (es) | Virión de virus adenoasociado para usar en el tratamiento de la epilepsia | |
| MX2020008932A (es) | Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos. | |
| PE20250736A1 (es) | Terapia genica para tratar la hemofilia a | |
| MX2021010134A (es) | Virus adenoasociado recombinante para el tratamiento de la neurodegeneracion de inicio en adultos asociada a grn. | |
| Sutherland et al. | Reovirus neurotropism and virulence are dictated by sequences in the head domain of the viral attachment protein | |
| Zhang et al. | Bone marrow mesenchymal stem cells overexpressing human basic fibroblast growth factor increase vasculogenesis in ischemic rats | |
| Kashiwakura et al. | Intra‐articular injection of mesenchymal stem cells expressing coagulation factor ameliorates hemophilic arthropathy in factor VIII‐deficient mice | |
| CO2022015313A2 (es) | Variantes de cápsides de aav y usos de los mismos | |
| UY38881A (es) | Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept | |
| CL2023001876A1 (es) | Proteínas de la cápside viral con especificidad para las células del tejido cardiaco | |
| US20230136849A1 (en) | Capsid-modified raav vector compositions and methods therefor | |
| JP6996728B2 (ja) | グルコーストランスポーター１発現用アデノ随伴ウイルスベクター | |
| FI3177313T3 (fi) | Telomeraasi-käänteistranskriptaasipohjaisia hoitoja sydäninfarktiin liittyvien tilojen hoitamiseksi | |
| MX2022002960A (es) | Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept. | |
| AR119955A1 (es) | Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept | |
| AR118177A1 (es) | Virus adeno-asociado recombinante para el tratamiento del inicio de la neurodegeneración en adultos asociadas con la grn | |
| CN120322252A (zh) | Upf1表达构建体 |